Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer

Código QR

Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer

Anne Rodallec,1 Jean-Michel Brunel,2 Sarah Giacometti,1 Helene Maccario,3 Florian Correard,3 Eric Mas,3 Caroline Orneto,4 Ariel Savina,5 Fanny Bouquet,5 Bruno Lacarelle,1 Joseph Ciccolini,1 Raphaelle Fanciullino11SMARTc Unit, Pharmacokinetics Laboratory, CRCM UMR U1068 CNRS UMR 7258 Aix Marseille Un...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rodallec A, Brunel JM, Giacometti S, Maccario H, Correard F, Mas E, Orneto C, Savina A, Bouquet F, Lacarelle B, Ciccolini J, Fanciullino R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	immunoliposomes – biopharmaceutical development –breast cancer – docetaxel - trastuzumab - HER2 Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/5e06676bf23b4bfa85b3f59357b9f471
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer
por: Rodallec A, et al.
Publicado: (2018)

From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer [Erratum]
por: Rodallec A, et al.
Publicado: (2018)

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
por: Linehan AS, et al.
Publicado: (2021)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
por: Jagosky M, et al.
Publicado: (2021)

Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells
por: Rodríguez-Serrano F, et al.
Publicado: (2016)

Data provision of PIK3CA gene diversity and recombinant plasmids preparation for control DNA in developing the trastuzumab predictive response diagnostic kit
por: DESRIANI DESRIANI, et al.
Publicado: (2016)

The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers
por: Hye Ryeon Kim, et al.
Publicado: (2021)

2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab
por: Nathalie I. Bouwer, et al.
Publicado: (2021)

The Role of Trastuzumab in Patients with HER2 Positive Small (pT1mi/a) Breast Cancers, a Multicenter Retrospective Study
por: Andrea Villasco, et al.
Publicado: (2021)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni MA, et al.
Publicado: (2021)

Multimodal Imaging Technology Effectively Monitors HER2 Expression in Tumors Using Trastuzumab-Coupled Organic Nanoparticles in Patient-Derived Xenograft Mice Models
por: Li Wen, et al.
Publicado: (2021)

Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
por: Kato Y, et al.
Publicado: (2021)

Reversible cardiotoxicity in a 54-year-old woman treated with trastuzumab
por: Martins,Sandro José, et al.
Publicado: (2012)

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
por: Belal Firwana, et al.
Publicado: (2012)

Probiotics for the Treatment of Docetaxel-Related Weight Gain of Breast Cancer Patients—A Single-Center, Randomized, Double-Blind, and Placebo-Controlled Trial
por: Zhang Juan, et al.
Publicado: (2021)

Multifunctional gold nanorods and docetaxel-encapsulated liposomes for combined thermo- and chemotherapy
por: Hua H, et al.
Publicado: (2017)

Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials
por: Vermunt M, et al.
Publicado: (2021)

Circulating Natural Autoantibodies to HER2-Derived Peptides Performed Antitumor Effects on Oral Squamous Cell Carcinoma
por: Xiu Liu, et al.
Publicado: (2021)

Estudos clínicos randomizados para registro de biossimilares trastuzumabe: uma revisão de escopo, Brasil, 2020
por: Tamiris Fazza Kelmer, et al.
Publicado: (2021)

Docetaxel-loaded multilayer nanoparticles with nanodroplets for cancer therapy
por: Oh KS, et al.
Publicado: (2016)

Functionalized docetaxel-loaded lipid-based-nanosuspensions to enhance antitumor efficacy in vivo
por: Pang X, et al.
Publicado: (2019)

Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
por: C Mirjolet, et al.
Publicado: (2017)

Design of theranostic nanomedicine (II): synthesis and physicochemical properties of a biocompatible polyphosphazene–docetaxel conjugate
por: Jun YJ, et al.
Publicado: (2017)

Co-Delivery of Docetaxel and Curcumin via Nanomicelles for Enhancing Anti-Ovarian Cancer Treatment
por: Hu Y, et al.
Publicado: (2020)

Enhanced antitumor effects by docetaxel/LL37-loaded thermosensitive hydrogel nanoparticles in peritoneal carcinomatosis of colorectal cancer
por: Fan R, et al.
Publicado: (2015)

Trastuzumab- and Fab′ fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo
por: Duan D, et al.
Publicado: (2018)

Glycan Profile Analysis of Engineered Trastuzumab with Rationally Added Glycosylation Sequons Presents Significantly Increased Glycan Complexity
por: Esteban Cruz, et al.
Publicado: (2021)

Pharmacokinetics and in vitro/in vivo antitumor efficacy of aptamer-targeted Ecoflex® nanoparticles for docetaxel delivery in ovarian cancer
por: Ghassami E, et al.
Publicado: (2018)

Anti-Cancer Activity Based on the High Docetaxel Loaded Poly(2-Oxazoline)s Micelles
por: Xu M, et al.
Publicado: (2021)

Novel T7-Modified pH-Responsive Targeted Nanosystem for Co-Delivery of Docetaxel and Curcumin in the Treatment of Esophageal Cancer
por: Deng L, et al.
Publicado: (2020)

Improved Anti-Triple Negative Breast Cancer Effects of Docetaxel by RGD-Modified Lipid-Core Micelles
por: Chen R, et al.
Publicado: (2021)

Características clínicas y pronóstico de pacientes con cáncer de mama HER2 positivo avanzado, en la era antes y después de terapias anti-HER2
por: SÁNCHEZ,CESAR, et al.
Publicado: (2018)

Anti-Cancer Activity Based on the High Docetaxel Loaded Poly(2-Oxazoline)s Micelles [Corrigendum]
por: Xu M, et al.
Publicado: (2021)

Candida guilliermondii Onychomycosis Involving Fingernails in a Breast Cancer Patient under Docetaxel Chemotherapy
por: Yassine Merad, et al.
Publicado: (2021)

Zafirlukast ameliorates Docetaxel-induced activation of NOD-like receptor protein 3 (NLRP3) inflammasome, mediated by sirtuin1 (SIRT1) in hepatocytes
por: Ziyi Guo, et al.
Publicado: (2021)

Co-Delivery of Docetaxel and Salinomycin to Target Both Breast Cancer Cells and Stem Cells by PLGA/TPGS Nanoparticles
por: Gao J, et al.
Publicado: (2019)

GE11 peptide-conjugated nanoliposomes to enhance the combinational therapeutic efficacy of docetaxel and siRNA in laryngeal cancers
por: Xu WW, et al.
Publicado: (2017)

Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer
por: Haruka Yamaguchi, et al.
Publicado: (2021)

Investigating the crucial roles of aliphatic tails in disulfide bond-linked docetaxel prodrug nanoassemblies
por: Yuequan Wang, et al.
Publicado: (2021)

Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles
por: Colzani B, et al.
Publicado: (2018)